Comparing three treatments for low-risk myelodysplasia with anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial compares three different medicines to see which works best for people with a blood condition called myelodysplasia (also called MDS) that causes anemia. It aims to find the safest and most effective option to improve blood counts and reduce symptoms like tiredness or shortness of breath.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with low-risk myelodysplasia (MDS) that has not yet turned into a more serious blood cancer.
- You have anemia (low red blood cells) that causes symptoms such as fatigue or shortness of breath, or you need regular red blood cell transfusions.
- You have not had prior treatment for MDS, except maybe up to two doses of an erythropoietin stimulating agent (like epoetin alfa or darbepoetin) if it was more than 8 weeks ago.
- Your kidney and liver function are within acceptable limits, and your blood counts meet certain minimum levels.
- You have not had cancer treatment or experimental drugs within 30 days before joining, and you are not taking certain other growth factors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
This trial is testing whether a combination of two drugs, luspatercept and darbepoetin alfa, can help people with lower-risk myelodysplastic syndromes (MDS) who need frequent red blood cell transfusions. The goal is to see if the combination reduces their need for transfusions.
This trial tests how well a biosimilar version of erythropoietin (a drug that boosts red blood cells) works in people with low-risk myelodysplastic syndrome (MDS) who have anemia. It aims to see if this treatment can safely improve low hemoglobin levels without needing more intensive therapies.
This study tests a drug called luspatercept, which helps the body make more red blood cells, in people with low-risk myelodysplastic syndromes (MDS) who have anemia. The goal is to see if it quickly improves blood counts, and you'll track your progress using a smartphone app.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
Hear when a new Myelodysplastic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.